XML 66 R46.htm IDEA: XBRL DOCUMENT v3.25.4
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2025
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of restricted stock unit activity
RSU activity for the year ended December 31, 2025 was as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Non-vested at December 31, 20241,475,656 $8.01 
Granted
1,203,010 $6.14 
Vested
(708,854)$8.22 
Forfeited
(47,920)$7.30 
Non-vested at December 31, 20251,921,892 $6.78 
Schedule of Stock Appreciation Rights award activity
SARs activity for the year ended December 31, 2025 was as follows:
Number of SharesWeighted Average Exercise Price
Aggregate Intrinsic Value (in millions) (a)
Outstanding, December 31, 2024
2,618,218 $11.20 $0.4 
Granted
745,300 $6.13 
Exercised
(80,979)$7.86 
Forfeited/Expired
(290,705)$15.69 
Outstanding, December 31, 20252,991,834 $9.59 $25.7 
(a)     Intrinsic value is defined as the difference between the current market value and the exercise price, for those SARs where the market price exceeds the exercise price.
Schedule of nonvested awards activity
The following table summarizes information related to outstanding and exercisable SARs at December 31, 2025:
SARs OutstandingSARs Exercisable
Range of Exercisable PricesVestedNon-vestedWeighted-Average Exercise Price per ShareWeighted-Average Remaining Contractual Life in YearsNumber ExercisableWeighted-Average Exercise Price per Share
$5.02 - $13.70
1,430,025 1,238,201 $8.30 6.281,430,025 $9.52 
$18.58 - $22.51
323,608 — 20.25 3.51323,608 20.25 
1,753,633 1,238,201 $9.59 5.981,753,633 $11.50 
Stock Appreciation Rights (SARs)  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of stock appreciation rights valuation assumptions
The table below summarizes the total SARs granted and the fair value of each grant estimated on the grant date using a Black-Scholes pricing model with the following assumptions:
Number of Shares Granted
Risk-free Interest RateDividend YieldExpected Life (Years)VolatilitySAR Grant PriceFair Value of SAR
March 2023 Grant404,5944.20 %— %6.062.6 %$7.45 $4.56 
May 2023 Grant48,4273.48 %— %6.063.0 %$9.31 $5.64 
March 2024 Grant567,9674.04 %— %6.063.4 %$8.20 $5.04 
March 2025 Grant711,4504.02 %— %6.065.1 %$6.03 $3.77 
June 2025 Grant33,8504.18 %— %6.065.7 %$8.20 $5.17 
Schedule of weighted-average grant-date fair value of unvested options
Weighted-average grant date fair value of non-vested SARs for the year ended December 31, 2025 was as follows:
Number of SharesWeighted-Average Grant Date Fair Value
Non-vested shares, December 31, 2024
928,964 $5.07 
Granted
745,300 3.83 
Vested
(407,647)5.26 
Forfeited
(28,416)4.88 
Non-vested shares, December 31, 2025
1,238,201 $4.27 
Performance Stock Units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of stock appreciation rights valuation assumptions
Under the 2013 Plan, the Company granted the following shares presented in the table below and estimated the fair value of these grants on the grant date using a Monte Carlo pricing model with the following assumptions:
PSUs Issued
Number of Shares Granted
Risk-free Interest rateDividend YieldExpected Life (Years)Volatility
Fair Value per PSU
March 2023 Grant758,965 4.67 %— %2.8243.9 %$10.91 
May 2023 Grant29,337 3.75 %— %2.6541.5 %$15.24 
March 2024 Grant778,702 4.26 %— %2.8139.8 %$12.04 
March 2025 Grant
1,041,593 3.91 %— %2.8358.2 %$7.38 
Schedule of weighted-average grant-date fair value of unvested options
A summary of the Company's non-vested PSU activity during the year ending December 31, 2025 was as follows:
Number of SharesWeighted-Average Grant Date Fair Value
Non-vested shares, December 31, 2024
1,457,388 $11.58 
Granted (a)
1,041,593 $7.38 
Vested, not issued (b)
(660,165)$11.10 
Vested and issued (c)
(912,459)$9.79 
Forfeited (d)
(83,839)$10.84 
Non-vested shares, December 31, 2025
842,518 $8.77 
(a) Includes 520,819 equity-settled and 520,774 cash-settled
(b) The measurement period for PSUs issued in 2023 ended on December 31, 2025. These shares vested but will not be issued until the Board certifies the measurement period results in early 2026. These shares will vest at 200%.
(c) Includes 692,370 equity-settled and 220,089 cash-settled, vested at 200%.
(d) Includes 78,340 equity-settled and 5,499 cash-settled.